FDA Inspection 1056899 — Samsung Biologics Co., Ltd.

Samsung Biologics Co., Ltd. — FEI 3010479596

The FDA completed an inspection of Samsung Biologics Co., Ltd. on Jun 26, 2018 in Yeonsu District. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Jun 26, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Yeonsu District (Korea (the Republic of))

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.